Shuttle Pharmaceuticals amends 8-K, says UDC merger not significant and financials not required
SHPH•Historical and pro forma financials withdrawn
It also withdraws the expected requirement to file UDC historical financial statements or pro forma financials, marking both as not applicable.
Management concluded UDC was not a “business” under ASC 805 at closing, so Regulation S-X Rule 3-05 and Article 11 financials were not required.
Amended 8-K reclassifies UDC merger disclosure
Shuttle Pharmaceuticals filed an amended 8-K to correct its earlier merger disclosure tied to the May 1, 2026 closing with United Dogecoin.
The amendment reclassifies the transaction as not reportable under Form 8-K Item 2.01, reversing the prior presentation as an acquisition.
